BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage ; volume:21 ; number:1 ; day:12 ; month:5 ; year:2021 ; pages:1-11 ; date:12.2021
BMC neurology ; 21, Heft 1 (12.5.2021), 1-11, 12.2021
- Urheber
-
Wang, Wei
Wang, Maode
Jiang, Haitao
Wang, Tuo
Da, Rong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-021-02224-6
- URN
-
urn:nbn:de:101:1-2021091219233182409517
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Wei
- Wang, Maode
- Jiang, Haitao
- Wang, Tuo
- Da, Rong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Diagnostic utility of BRAF V600E mutation testing in thyroid nodules in elderly patients
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer